MX2007003954A - Vlp-antigen conjugates and their uses as vaccines. - Google Patents
Vlp-antigen conjugates and their uses as vaccines.Info
- Publication number
- MX2007003954A MX2007003954A MX2007003954A MX2007003954A MX2007003954A MX 2007003954 A MX2007003954 A MX 2007003954A MX 2007003954 A MX2007003954 A MX 2007003954A MX 2007003954 A MX2007003954 A MX 2007003954A MX 2007003954 A MX2007003954 A MX 2007003954A
- Authority
- MX
- Mexico
- Prior art keywords
- vlp
- antigen
- compositions
- vaccines
- rna
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 4
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000005867 T cell response Effects 0.000 abstract 1
- 230000005875 antibody response Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising a virus-like particle (VLP) of an RNA-bacteriophage and at least one antigen, wherein the VLP is recombinantly produced in a host, and wherein the amount of host RNA with secondary structure comprised by the VLP is at most 20% of the amount of host RNA with secondary structure originally comprised by the VLP; and wherein the VLP and the at least one antigen are linked with one another. The invention also provides methods for producing the compositions of the invention. The compositions of the invention are useful in the production of vaccines for the treatment of diseases, disorders and conditions. Furthermore, the compositions of the invention are particularly useful to efficiently induce strong antibody responses against the antigen within the indicated context while lowering or eliminating unwanted T cell responses.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61563704P | 2004-10-05 | 2004-10-05 | |
| EP05105228 | 2005-06-14 | ||
| PCT/EP2005/055009 WO2006037787A2 (en) | 2004-10-05 | 2005-10-05 | Vlp-antigen conjugates and their uses as vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007003954A true MX2007003954A (en) | 2007-06-14 |
Family
ID=39445825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007003954A MX2007003954A (en) | 2004-10-05 | 2005-10-05 | Vlp-antigen conjugates and their uses as vaccines. |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JP2008515851A (en) |
| BR (1) | BRPI0516476A (en) |
| IL (1) | IL181228A0 (en) |
| MX (1) | MX2007003954A (en) |
| NZ (1) | NZ554388A (en) |
| RU (1) | RU2417793C2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012125190A (en) * | 2010-12-15 | 2012-07-05 | Kakei Gakuen | Linker peptide for making association unit |
| WO2022230485A1 (en) * | 2021-04-26 | 2022-11-03 | 国立大学法人長崎大学 | Vaccine composition for transpulmonary or transnasal administration |
| WO2024005668A1 (en) * | 2022-06-28 | 2024-01-04 | Андрей Николаевич ВОЛОГОДСКИЙ | Method for producing bacteriophage virus-like particles |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1150712T1 (en) * | 1999-02-05 | 2009-02-28 | Merck & Co Inc | Human papilloma virus vaccine formulations |
| EP2196217A1 (en) * | 2001-09-14 | 2010-06-16 | Cytos Biotechnology AG | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
-
2005
- 2005-10-05 NZ NZ554388A patent/NZ554388A/en not_active IP Right Cessation
- 2005-10-05 JP JP2007535158A patent/JP2008515851A/en active Pending
- 2005-10-05 BR BRPI0516476-1A patent/BRPI0516476A/en not_active IP Right Cessation
- 2005-10-05 RU RU2007116717/10A patent/RU2417793C2/en not_active IP Right Cessation
- 2005-10-05 MX MX2007003954A patent/MX2007003954A/en not_active Application Discontinuation
-
2007
- 2007-02-08 IL IL181228A patent/IL181228A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0516476A (en) | 2008-09-02 |
| JP2008515851A (en) | 2008-05-15 |
| IL181228A0 (en) | 2008-04-13 |
| RU2007116717A (en) | 2008-11-20 |
| NZ554388A (en) | 2010-01-29 |
| RU2417793C2 (en) | 2011-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006037787A3 (en) | Vlp-antigen conjugates and their uses as vaccines | |
| WO2009080823A3 (en) | Nerve growth factor conjugates and uses thereof | |
| Vecchi et al. | Aluminum adjuvant dose guidelines in vaccine formulation for preclinical evaluations | |
| IL165003A0 (en) | Ghrelin-carrier conjugates | |
| WO2005009463A3 (en) | Antigen-presenting cell vaccines and methods of use thereof | |
| ATE447967T1 (en) | PACKAGING OF IMMUNO-STIMULATIVE CPG IN VIRUS-LIKE PARTICLES: PRODUCTION METHOD AND USE | |
| UA102994C2 (en) | ANTIBODY THAT SPECIFICALLY BINDS TO IgE/M1' AND INDUCES APOPTOSIS IN IgE-EXPRESSING B-CELLS | |
| WO2004084936A8 (en) | Modified free-living microbes, vaccine compositions and methods of use thereof | |
| WO2007095320A3 (en) | Hpv antigens, vaccine compositions, and related methods | |
| DE602004031017D1 (en) | COMPOSITION PACKAGED VIRUSIC PARTICLES INCLUDING THE IMPROVEMENT OF AN IMMUNE RESPONSE | |
| NO20064059L (en) | Albumin fusion proteins | |
| UA116614C2 (en) | FACTOR ANTIBODY AND ITS APPLICATION | |
| MX2011000767A (en) | Neutralizing anti-influenza a virus antibodies and uses thereof. | |
| ATE384785T1 (en) | PRODUCTION OF VIRUSES, VIRUS ISOLATES, AND VACCINES | |
| WO2011156774A3 (en) | Multivalent glycopeptide constructs and uses thereof | |
| BRPI0610093A2 (en) | pharmaceutical composition, and method for preventing or treating a disease associated with alpha-beta amyloid deposits in a patient's brain | |
| BRPI0511751A (en) | Medical Uses of Non-Human TNF Vehicle Peptide Conjugates | |
| BR0213950A (en) | Antigen Arrangements for the Treatment of Allergic Eosinofolic Diseases | |
| DK1441764T3 (en) | Antigen Arrays Including RANKL for the Treatment of Bone Disease | |
| WO2005068639A3 (en) | Particle-induced ghrelin immune response | |
| DE502005010170D1 (en) | NEW LOW-ACTIVE BETA-2 AGONISTS AND THEIR USE AS DRUGS | |
| WO2004031231A3 (en) | Genes and polypeptides relating to prostate cancers | |
| NO20012135L (en) | Enhanced vaccines | |
| WO2005120558A3 (en) | Methods for making compositions comprising heat shock proteins or alpha-2-macroglobulin for the treatment of cancer and infectious disease | |
| Taleghani et al. | Immunogenicity of HPV and HBV vaccines: adjuvanticity of synthetic analogs of monophosphoryl lipid A combined with aluminum hydroxide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |